NCT01485874 - Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Ovarian Cancer

Interventions

DRUG

Doxil (Pegylated Liposomal Doxorubicin)

Phases I and II: 40 mg/m2 IV over 60 min (+/- 15 min) on day 1 of 28-day cycle

DRUG

BIBF 1120

"Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid~Phase II: MTD orally, bid, day 2 of 28-day cycle"

Trial Locations (2)

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

University of Wisconsin, Madison